ClinicalTrials.gg

Program

Albumin-Bound Paclitaxel

Also written as “ABI-007”, “nab-paclitaxel” and “Nab-paclitaxel”.

Its studies are mostly in Pancreatic Neoplasms · Breast Neoplasms · Carcinoma, Non-Small-Cell Lung · Triple Negative Breast Neoplasms · Melanoma, led by 11 companies.

Furthest: phase 4, since May 28, 201451 company-led studies, 3 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibb380 open or runningphase 4since May 28, 2014Sep 30, 2002none ahead
CSPC Pharmaceutical Group31 open or runningphase 3since Aug 15, 2017Aug 15, 2017none ahead
Theriva Biologics SL20 open or runningphase 1since Jan 21, 2014Jan 21, 2014none ahead
academic-thoracic-oncology-medical-investigators-consortium10 open or runningphase 2since Mar 24, 2016Mar 24, 2016none ahead
Astellas Pharma10 open or runningphase 1since Nov 6, 2009Nov 6, 2009none ahead
ebg-medaustron-gmbh11 open or runningno phasesince May 10, 2021May 10, 2021Dec 31, 2026NCT04894643
Lee's Pharmaceutical10 open or runningphase 1since Sep 8, 2020Sep 8, 2020none ahead
Novartis10 open or runningphase 2since Jul 1, 2008Jul 1, 2008none ahead
NovoCure10 open or runningphase 2since Feb 29, 2024Feb 29, 2024none ahead
Otsuka10 open or runningphase 2since Apr 16, 2008Apr 16, 2008none ahead
synergene-therapeutics-inc11 open or runningphase 2since Dec 18, 2014Dec 18, 2014Dec 2026phase 2 · NCT02340117

Also a collaborator on its studies: Gilead Sciences, Pfizer, Criterium and Shanghai Pharmaceuticals.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 36 studies since Sep 30, 2002.

  1. Oct 1, 2014Phase 1 study in Pancreatic NeoplasmsBristol-Myers Squibb · NCT02267707 · 1 enrolled · United States, Germany
  2. Nov 10, 20142 phase 2 studiesBristol-Myers Squibb · NCT02289456, NCT02301143
  3. Dec 3, 2014Phase 1 study in Breast NeoplasmsBristol-Myers Squibb · NCT02309177 · 114 enrolled · United States
  4. Dec 18, 2014synergene-therapeutics-inc’s first study: phase 2 study in Pancreatic NeoplasmsNew to synergene-therapeutics-incsynergene-therapeutics-inc · NCT02340117 · 28 enrolled · United States
  5. Nov 30, 2015Phase 1 study in Pancreatic NeoplasmsBristol-Myers Squibb · NCT02620800 · 12 enrolled · United States
  6. Mar 24, 2016academic-thoracic-oncology-medical-investigators-consortium’s first study: phase 2 study in Pancreatic NeoplasmsNew to academic-thoracic-oncology-medical-investigators-consortiumacademic-thoracic-oncology-medical-investigators-consortium · NCT02723331 · 48 enrolled · United States
  7. Jun 9, 2017Phase 2 study in Colorectal NeoplasmsBristol-Myers Squibb · NCT03184870 · 332 enrolled · United States, Australia, Belgium and more
  8. Aug 15, 2017CSPC Pharmaceutical Group’s first study: phase 3 study in Carcinoma, Non-Small-Cell LungNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT03262948 · 388 enrolled
  9. Nov 6, 2017Phase 2 study in Advanced Pancreatic CancerBristol-Myers Squibb · NCT03336216 · 205 enrolled · United States, Canada, Denmark and more
  10. Sep 8, 2020Lee's Pharmaceutical’s first study: phase 1 study in Advanced Urothelial CarcinomaNew to Lee's PharmaceuticalLee's Pharmaceutical · NCT04603846 · 20 enrolled · China
  11. May 10, 2021ebg-medaustron-gmbh’s first study: no phase study in Pancreatic NeoplasmsNew to ebg-medaustron-gmbhebg-medaustron-gmbh · NCT04894643 · 10 planned · Austria
  12. Apr 12, 2022Phase 1 study in Advanced Solid TumorCSPC Pharmaceutical Group · NCT05344742 · 116 enrolled
  13. Feb 29, 2024NovoCure’s first study: phase 2 study in Pancreatic NeoplasmsNew to NovoCureNovoCure · NCT06390059 · 84 enrolled · Czechia, Germany, Spain and more
  14. Jul 24, 2025Phase 1 study in BioequivalenceCSPC Pharmaceutical Group · NCT07096869 · 28 planned · China

Ahead

  1. Dec 2026Primary completion: phase 2 study in Pancreatic Neoplasmssynergene-therapeutics-inc · NCT02340117
  2. Dec 31, 2026Primary completion: no phase study in Pancreatic Neoplasmsebg-medaustron-gmbh · NCT04894643

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 51 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07096869Bioequivalence · China1RecruitingCSPC Pharmaceutical GroupDec 31, 202528
NCT06390059Pancreatic Neoplasms · Czechia, Germany, Spain and more2CompletedNovoCureNov 18, 202584
NCT05344742Advanced Solid Tumor1UNKNOWNCSPC Pharmaceutical GroupMar 2024116
NCT04894643Pancreatic Neoplasms · Austria–Recruitingebg-medaustron-gmbhDec 31, 202610
NCT04603846Advanced Urothelial Carcinoma · China1UNKNOWNLee's PharmaceuticalOct 1, 202220
NCT03336216Advanced Pancreatic Cancer · United States, Canada, Denmark and more2CompletedBristol-Myers SquibbJun 1, 2023205
NCT03262948Carcinoma, Non-Small-Cell Lung3UNKNOWNCSPC Pharmaceutical GroupOct 1, 2019388
NCT03184870Colorectal Neoplasms · United States, Australia, Belgium and more2CompletedBristol-Myers SquibbApr 6, 2023332
NCT02723331Pancreatic Neoplasms · United States2Completedacademic-thoracic-oncology-medical-investigators-consortiumDec 8, 202248
NCT02620800Pancreatic Neoplasms · United States1CompletedBristol-Myers SquibbOct 29, 201812
NCT02340117Pancreatic Neoplasms · United States2Active, not recruitingsynergene-therapeutics-incDec 202628
NCT02309177Breast Neoplasms · United States1CompletedBristol-Myers SquibbSep 12, 2018114
NCT02301143Pancreatic Neoplasms · United States, Canada, France and more2CompletedBristol-Myers SquibbNov 21, 2017107
NCT02289456Carcinoma, Non-Small-Cell Lung · United States2CompletedBristol-Myers SquibbFeb 22, 201740
NCT02267707Pancreatic Neoplasms · United States, Germany1TerminatedBristol-Myers SquibbFeb 10, 20161
NCT02250326Carcinoma, Non-Small-Cell Lung · United States, Canada, France and more2CompletedBristol-Myers SquibbJul 17, 2017240
NCT02151149Carcinoma, Non-Small-Cell Lung · United States4CompletedBristol-Myers SquibbJul 14, 2017143
NCT02103062Colorectal Neoplasms · France2CompletedBristol-Myers SquibbNov 10, 201441
NCT02045602Neoplasms · Spain1CompletedTheriva Biologics SLMay 201942
NCT02045589Neoplasms · Spain1CompletedTheriva Biologics SLOct 20168
NCT02027428Carcinoma, Squamous Cell · United States, Germany, Italy and more3CompletedBristol-Myers SquibbSep 15, 2017427
NCT02017015Pancreatic Neoplasms · China2CompletedBristol-Myers SquibbJun 1, 201583
NCT01964430Pancreatic Neoplasms · United States, Australia, Austria and more3CompletedBristol-Myers SquibbJun 30, 2022866
NCT01962103Neuroblastoma · United States, Canada, France and more2CompletedBristol-Myers SquibbDec 5, 2017107
NCT01933061Melanoma2WithdrawnBristol-Myers SquibbJan 20140
NCT01881230Breast Neoplasms · United States, Australia, Austria and more3CompletedBristol-Myers SquibbOct 28, 2016191
NCT01010945Adenocarcinoma · United States1CompletedAstellas PharmaJan 25, 201219
NCT00864253Melanoma · United States, Australia, Canada and more3CompletedBristol-Myers SquibbJun 1, 2012529
NCT00844649Pancreatic Neoplasms · United States, Australia, Austria and more3CompletedBristol-Myers SquibbSep 17, 2012861
NCT00709761Breast Neoplasms · United States2CompletedNovartisJan 5, 201160
NCT00661167Stomach Neoplasms · Japan2CompletedOtsukaMay 201156
NCT00540514Carcinoma, Non-Small-Cell Lung · United States, Canada3CompletedBristol-Myers SquibbOct 1, 20091,052
NCT00518284Peripheral Vascular Diseases · United States2TerminatedBristol-Myers SquibbAug 20096
NCT00456846Breast Neoplasms · Canada2TerminatedBristol-Myers SquibbDec 11, 2012123
NCT00407407Fallopian Tube Neoplasms · United States1TerminatedBristol-Myers SquibbFeb 1, 20086
NCT00398086Pancreatic Neoplasms · United States2CompletedBristol-Myers SquibbSep 1, 200867
NCT00394251Breast Neoplasms · United States2CompletedBristol-Myers SquibbMar 1, 2007197
NCT00394082Breast Neoplasms · United States2CompletedBristol-Myers SquibbSep 1, 200950
NCT00281528Breast Neoplasms · United States, Puerto Rico2TerminatedBristol-Myers SquibbJul 1, 2010208
NCT00274456Breast Neoplasms · Ukraine2CompletedBristol-Myers SquibbMar 1, 2008302
NCT00274443Carcinoma, Non-Small-Cell Lung · Russian Federation2CompletedBristol-Myers SquibbJun 1, 2007250
NCT00249002Hemodialysis Graft Dysfunction · United States2TerminatedBristol-Myers SquibbNov 1, 20079
NCT00140140Neoplasm Metastasis · United States2TerminatedBristol-Myers SquibbFeb 200816
NCT00124943Coronary Restenosis2CompletedBristol-Myers SquibbAug 2009112
NCT00107094Breast Neoplasms · United States1CompletedBristol-Myers Squibb30
NCT00093145Breast Neoplasms · United States2CompletedBristol-Myers SquibbOct 1, 200832
NCT00093119Melanoma · United States2CompletedBristol-Myers SquibbFeb 200575
NCT00073723Carcinoma, Non-Small-Cell Lung · United States2CompletedBristol-Myers Squibb75
NCT00046527Breast Neoplasms · United States3CompletedBristol-Myers Squibb460
NCT00046514Breast Neoplasms · United States2CompletedBristol-Myers Squibb100
NCT00046423Neoplasms · United States1CompletedBristol-Myers Squibb20

How it is read

Names in the registry

  • “ABI-007”, 15 entries
  • “nab-paclitaxel”, 13 entries
  • “Nab-paclitaxel”, 12 entries
  • “Nab-Paclitaxel”, 9 entries
  • “nab-Paclitaxel”, 6 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.